[Treatment of hyperuricemia using daily doses of 50 and 25mg of benzbromarone].
By treating 16 hyperuricemic patients each with 25 and 50 mg of Benzbromarone a significant decrease of the uric acid concentration in the serum into the normal range is achieved. On the 5th and 6th day after beginning the treatment the dosage of 25 mg of Benzbromarone renders a morning value of 5,3 +/- 1,0 and an evening value of 5,0 +/- 0,9 mg/100 ml. After administration of 50 mg of Benzbromarone there is also prevailing a steady-state behaviour on the 5th and 6th day for the uric acid concentration in the serum. Thereby the morning value is 3,7 +/- 0,8 mg/100 ml and th evening value 3,4 +/- 0,9 mg/100 ml. After both dosages an increased urate elimination occurs initially during the 1st, 2nd and 3rd day after beginning of the therapy. However, after having achieved therapeutically reduced uric acid levels, the uric acid elimination from the 4th, 5th and 6th day partially ranges below those values existing before beginning of the therapy. During a chronic treatment no hyperuraturia can be observed on account of the therapeutically reduced serum concentrations. Consequently an increased risk towards a formation of urate calculi is not given under the long-term treatment.
D001553:Benzbromarone / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006073:Gout / Q000188:drug therapy; D006801:Humans; D008297:Male; D014527:Uric Acid / Q000097:blood* / Q000652:urine
D014527:Uric Acid; D001553:Benzbromarone
Hyperurikämie-Behandlung mit Tagesdosen von 50 und 25 mg Benzbromaron.